Viking Therapeutics: Full-Speed Ahead
Viking Therapeutics is aggressively advancing its GLP-1 pipeline, with two pivotal Phase 3 trials now underway or imminent. VKTX's Phase 2 oral data showed up to 14.7% weight loss in 13 weeks, positioning it competitively against current market leaders. With a $3.5B market cap and $706M cash, VKTX trades at a compelling discount to recent sector M&A benchmarks.
VKTX Posts Wider-Than-Expected Loss in Q4, Stock Up on Pipeline Updates
Viking Therapeutics posts a wider-than-expected Q4 loss, but shares jump as it advances oral VK2735 into late-stage obesity studies.
Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call Transcript
Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call Transcript
Viking Therapeutics plans to advance oral obesity drug to late-stage trial
Viking Therapeutics said on Wednesday that it plans to test its experimental oral obesity drug in a late-stage study later this year.
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market
Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $29.06, signifying a -3.9% move from its prior day's close.
Viking Therapeutics to Report Q4 Earnings: Here's What to Know
VKTX heads into Q4 earnings with investor focus on VK2735's late-stage obesity studies that are witnessing rapid enrollment momentum.
Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts
Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $32.22, moving 5.49% from the previous trading session.
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts
Viking Therapeutics, Inc. (VKTX) closed at $34.09 in the latest trading session, marking a +2.13% move from the prior day.
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know
Viking Therapeutics, Inc. (VKTX) reached $31.86 at the closing of the latest trading day, reflecting a -7.21% change compared to its last close.
Viking Therapeutics, Inc. (VKTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Viking Therapeutics, Inc. (VKTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know
Viking Therapeutics, Inc. (VKTX) reached $31.99 at the closing of the latest trading day, reflecting a +1.07% change compared to its last close.
VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug
Viking Therapeutics completes enrollment in a phase I maintenance study of VK2735, testing flexible oral and injectable dosing after initial weight loss in obese adults.
